Technology
Health
Pharmaceutical

Roche

$34.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.25 (0.74%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Roche and other stocks, options, ETFs, and crypto commission-free!

About

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. Read More The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. RHHBY is listed on the OTCQX International Premier market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).

Employees
94,442
Headquarters
Basel, Basel-Stadt (Basle Town)
Founded
1896
Market Cap
188.88B
Price-Earnings Ratio
21.55
Dividend Yield
2.22
Average Volume
1.19M
High Today
$34.08
Low Today
$33.69
Open Price
$33.69
Volume
625.42K
52 Week High
$34.98
52 Week Low
$26.30

Collections

Technology
Health
Pharmaceutical
Healthcare
Europe (Non-UK)
Europe

News

Yahoo FinanceMay 23

Synlogic Enters Cancer Collaboration with Roche

Synlogic, Inc. SYBX announced that it has entered a new collaboration with large pharma company, Roche RHHBY. Synlogic will develop its Synthetic Biotic medicine, SYNB1891, in combination with Roche’s PD-L1 inhibitor, Tecentriq (atezolizumab), as a treatment for advanced solid tumors. SYNB1891 is a pre-clinical stage candidate. Synlogic is expected to file an investigational new drug (“IND”) application with the FDA in the second half of 2019to initiate a phase I study to evaluate SYNB1891 as monotherapy a...

11
Seeking AlphaMay 22

Synlogic teams up with Roche in potential combo therapy for solid tumors

Synlogic (NASDAQ:SYBX) will collaborate with Roche (OTCQX:RHHBY) on clinical studies evaluating the combination of SYNB1891, a STING agonist, and Tecentriq (atezolizumab) in patients with advanced solid tumors.

37
Seeking AlphaMay 16

Roche's entrectinib shows positive action in early-stage cancer study

Preliminary results in a Phase 1/2 clinical trial, STARTRK-NG, evaluating Roche (OTCQX:RHHBY) unit Genentech's entrectinib (RXDX-101) in children and adolescents with treatment-resistant solid tumors with or without NTRK, ROS1 or ALK gene fusions showed a 100% (n=11/11) response rate in subjects with the gene fusions, including five with high-grade tumors in the central nervous system.

63
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.